

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PHA 4293
(3167/4Z)

Application of: Pharmacia Corporation
Inventor: John P. McKearn et al.
Serial No.: 09/857,873 Art Unit 1614
Filed: October 5, 2001
For: METHOD OF USING CYCLOOXYGENASE-2 INHIBITOR AND ONE OR
MORE ANTINEOPLASTIC AGENTS AS COMBINATION THERAPY IN
THE TREATMENT OF NEOPLASIA
Our File No.: PHA 4293 (3167/4Z)

POWER OF ATTORNEY

Pharmacia Corporation, assignee of the entire right, title and interest in and to the invention of the above application, hereby appoint Donald G. Leavitt (17,626), John K. Roedel, Jr. (25,914), Michael E. Godar (28,416), Edward J. Hejlek (31,525), William E. Lahey (26,757), Richard G. Heywood (18,224), Frank R. Agovino (27,416), Kurt F. James (33,716), Paul I. J. Fleischut (35,513), Vincent M. Keil (36,838), Robert M. Evans, Jr. (36,794), Robert M. Bain (36,736), Kathleen M. Petrillo (35,076), Richard L. Bridge (40,529), Christopher M. Goff (41,785), Derick E. Allen (43,468), Michael G. Munsell (43,820), Anthony R. Kinney (44,834), Brian P. Klein (44,837), Donald W. Tuegel (45,424), Steven M. Ritchey (46,321), Kathryn J. Doty (40,593), James J. Barta, Jr. (47,409), James E. Davis (47,516), Richard A. Schuth (47,929), Jennifer E. Hoekel (48,330), Timothy B. McBride (47,781), David L. Howard (41,502), Andrew N. Claerbout (50,202), Thomas F. Maloney (50,156), James D. Harper (51,781), Jeffrey S. Ellsworth (51,650), Patricia K. Fitzsimmons (52,894), Kofi Adzamlı (52,545), Andrew C. Wegman (P-54,530) and Bradley S. Schammel (P-54,667), all of the law firm of **SENNIGER, POWERS, LEAVITT & ROEDEL**, One Metropolitan Square, 16th Floor, St. Louis, Missouri 63102; and S. Christopher Bauer (42,305), Dennis A. Bennett (34,547), James C. Forbes (39,457), Kalim S. Fuzail (45,805), J. Timothy Keane (27,808), Robert M. Kennedy (28,026), Karen B. King (41,898), Verne A. Luckow (45,950), Scott J. Meyer (25,275), Richard A. Mueller (41,094), Philip B. Polster, II (43,864), Rachel Polster (47,004), Joseph R. Schuh (48,180), James M. Warner (45,199) and Scott A. Williams (39,876), all of **PHARMACIA CORPORATION**, Global Patent Department, Post Office Box 1027, St. Louis, Missouri 63006, or their duly appointed associate, attorneys in said application, with full power of substitution, revocation and addition, to continue prosecution of this application, to make alterations and amendments therein, and to transact all business in the Patent and Trademark Office in connection therewith.

PHARMACIA CORPORATION

Signature: J. Timothy Keane
Name: J. Timothy Keane
Title: _____
Date: 11 Aug 2003

J. Timothy Keane
Chief Counsel & Sr. Director
Pharmacia Corporation
Global Intellectual Property
St. Louis & Skokie Sites